People · Operator
Named in public records as an officer, director or promoter · active 2017–2025 · Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Abintus Bio, Inc. | — | Biotechnology | Series A | $13.7M | $177.4M | 2022 |
| Zucara Therapeutics Inc. | — | Biotechnology | Series A | $5.0M | $19.7M | 2025 |
| Kramerica Printing, LLC | — | Other | Seed | $1.8M | $33.5M | 2017 |
Michael A Martin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael A Martin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Chris A Garabedian | 1 | 1 |
| Claude A Piche | 1 | 1 |
| Michael Midmer | 1 | 1 |
| Richard A Liggins | 1 | 1 |
| Janet A Grove | 1 | 1 |
| Fred A Callori | 1 | 1 |
| Carlos E. Ibanez | 1 | 1 |
| Robert Anthony Williamson | 1 | 1 |
| Troy E. Wilson | 1 | 1 |
| Nicholas A. Boyle, Ph.D. | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.